Wondering how researchers calculated that improvement?
The participants who took lecanemab experienced a 0.45-point reduction on the scale.
The companies say more data will be published in November.
Lara Antal / Verywell
The thing that makes me a little cautious is the magnitude of that difference.
What Is the Clinical Dementia Rating scale?
Its an 18-point scale, and people are given points based on how they score in each area.
Then all scores are summed up.
Does a 0.45-Point Difference Matter?
This [0.45-point finding] is sort of the cusp of that minimal difference, she said.
Is 18 Months Long Enough to See Cognitive Change?
Thats the average rate of progression.
Tousi added that lecanemab might help slow the speed of decline, but it wont stop it from progressing.
Or does that look like its the maximum difference this drug is likely to achieve?
Lecanemab is administered via intravenous infusion, which can be taxing on patients and their families.
Those more severe patients will likely not benefit from this possible advancement.
The medication is not going to stop the diseasethat is very important for families to know, Tousi said.
Were just hoping the days you’re able to remain independent are going to be longer.
